Recent news & events:
-
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
search:
Follow our blog:
Enter your email address to follow this blog and receive notifications of new posts by email.1387-P — 2016 ePoster Electronic Documentation of Lifestyle Counseling in Primary Care Is Associated with Lower Risk of Cardiovascular Events in Patients with Diabetes Health Care Delivery/Economics- Presented Sunday – Jun 12, 2016 12:00 PM – 2:00 PM
HUABING ZHANG,NAOSHI HOSOMURA, MARIA SHUBINA, DONALD C. SIMONSON, MARCIA A. TESTA, ALEXANDER TURCHIN Electronic Documentation of Lifestyle Counseling in.1216-P — 2016 ePoster Effect of Medication Reconciliation on Emergency Department Visits and Hospitalizations in Patients with Diabetes Health Care Delivery/Economics- Presented Sunday – Jun 12, 2016 12:00 PM – 2:00 PM
OLUKAYODE SOSINA, HUABING ZHANG, MARIA SHUBINA,SONALI P. DESAI, DONALD C. SIMONSON, MARCIA A. TESTA Effect of Medication Reconciliation on.1235-P — 2016 ePoster Patient-Centered Outcomes and Socio-Demographic Predictors of Diabetes Treatment Effectiveness Health Care Delivery Economics – Presented Sunday – Jun 12, 2016 12:00 PM – 2:00 PM
MARCIA A. TESTA, MAXWELL SU, ALEXANDER TURCHIN, DONALD C. SIMONSON, Boston, MA Patient-Centered Outcomes and Socio-Demographic Predictors of Diabetes Treatment.Recent news & events:
-
799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
1520-P: Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
search:
Follow our blog:
Enter your email address to follow this blog and receive notifications of new posts by email.
In 1987, Phase V Technologies, Inc. was founded by the University of Connecticut Research and Development Corporation and named to signify its mission to extend drug development beyond Phase 1 through Phase 4 endpoints and data collection methods. The term “Phase V®” was trademarked as the “fifth phase” of drug development to signify technological advancements in the collection of direct-from-patient assessments and patient-centered outcomes.
Infomation
- Call us: 1-781-237-7737
- Address: 20 Walnut Street, Suite 110, Wellesley Hills, MA 02481
- Need Help: phasev@phasevtechnologiesinc.com
- work time: Mon - Fri : 9.00 am - 5.00 pm
Newsletter
Keep up to date with news from UNSNEC Business. A once a week email with no spam.Recent Posts
Copyright © UNSNEC 2019. All Right Reserved